SCHEMBL19697449

SCHEMBL19697449

C=CCOCN1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 20/20 0.68
▸ EGFR P00533 3/20 0.68
▸ TEC P42680 3/20 0.68
▸ BMX P51813 3/20 0.68
▸ LYN P07948 3/20 0.68
▸ TXK P42681 2/20 0.68
▸ FGFR2 P21802 2/20 0.68
▸ ITK Q08881 2/20 0.68
▸ LCK P06239 2/20 0.68
▸ BLK P51451 2/20 0.68
▸ RIPK2 O43353 1/20 0.68
▸ NR1I2 O75469 1/20 0.68
▸ SLC22A3 O75751 1/20 0.68
▸ LATS1 O95835 1/20 0.68
▸ NUDT14 O95848 1/20 0.68
▸ ABL1 P00519 1/20 0.68
▸ ERBB2 P04626 1/20 0.68
▸ FYN P06241 1/20 0.68
▸ PGR P06401 1/20 0.68
▸ CSF1R P07333 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22625584 1.00 BTK (0.68) BTKEGFRTECBMXLYN
SCHEMBL18476813 0.90 BTK (0.71) BTKEGFRTECBMXLYN
SCHEMBL18131947 0.90 BTK (0.71) BTKEGFRTECBMXLYN
SCHEMBL23226086 0.86 BTK (0.74) BTKEGFRTECBMXLYN
SCHEMBL23226083 0.86 BTK (0.74) BTKEGFRTECBMXLYN
SCHEMBL16075647 0.85 BTK (0.73) BTKEGFRTECBMXLYN
SCHEMBL22002211 0.85 BTK (0.71) BTKEGFRTECBMXLYN
SCHEMBL16078937 0.85 BTK (0.73) BTKEGFRTECBMXLYN
SCHEMBL18663850 0.85 BTK (0.76) BTKEGFRTECBMXLYN
SCHEMBL4910818 0.85 BTK (0.79) BTKEGFRTECBMXLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170354655-A1 TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS PHARMACYCLICS LLC 2017-12-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170354655-A1 TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS BTK, TLR3, TLR9 BTK 1/4885EGFR 366/4885TEC 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback